Longeveron (LGVN) Net Cash Flow Growth (3y) (2023 - 2026)
Longeveron (LGVN) Net Cash Flow Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -50.33% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 38.47% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 33.37% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -29.82% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Longeveron | 15.18 Bn | 15.16 Bn | 264,000.00 | 58.88% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 58.88% |
| Dec 31, 2025 | -14.28% |
| Sep 30, 2025 | 45.27% |
| Jun 30, 2025 | -27.91% |
| Mar 31, 2025 | -11.63% |
| Dec 31, 2024 | -30.51% |
| Sep 30, 2024 | 51.34% |
| Jun 30, 2024 | 76.65% |
| Mar 31, 2024 | -28.61% |
| Dec 31, 2023 | 92.73% |
| Sep 30, 2023 | -43.31% |
| Jun 30, 2023 | -39.79% |
| Mar 31, 2023 | -122.52% |